LGND

#1364
Ligand Pharmaceuticals Incorporated - Common Stock
235.3 0 USD
+0.27%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
233.72
237.15
Range Annuel
2.29
247.38
Changement quotidien
+0.27%
Changement Mensuel
+4.64%
Evolution sur 6 mois
+17.72%
Changement Annuel
+25.75%
Clôture Précédente
234.6 6
Open
234.7 9
Low
233.7 2
High
237.1 5
Volume
21
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 4.72 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
30.84
ratio cours/chiffre d'affaires
14.31
Dividende par action
2.5
Rendement du dividende (%)
1.32

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Nouvelles